LAPAROSCOPIC POWER MORCELLATORS MARKET ANALYSIS

Laparoscopic Power Morcellators Market Size and Trends

Global laparoscopic power morcellators market is estimated to be valued at USD 137.4 Mn in 2024 and is expected to reach USD 225.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.

Discover market dynamics shaping the industry: Request sample copy

The global laparoscopic power morcellators market is expected to witness positive growth over the forecast period due to increasing gynecological procedures worldwide and rising obese population. Laparoscopic power morcellators are used in laparoscopic procedures to cut tissue or organs into smaller pieces so that they can be easily removed through smaller incisions. These devices help in minimally invasive procedures and enable faster recovery for patients.

Market Driver – Increasing prevalence of Uterine Leiomyomata (UL) in women

Increasing prevalence of Uterine Leiomyomata (UL) in women is expected to drive the growth of the global laparoscopic power morcellators market over the forecast period. Increasing prevalence of uterine fibroids in women; will in turn increase the adoption of laparoscopic power morcellators which is expected to drive the growth of the global laparoscopic power morcellators market over the forecast period. For instance, according to an article published in August 2021, the prevalence and burden of symptomatic uterine leiomyomata which is also called as fibroids and benign tumors of the uterus among women was approximately one in 20 or 5% or 13.6 million women globally.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Companies are focused on developing new laparoscopic power morcellators with 510 (k) product clearance based on new regulatory guidelines from the regulatory authorities such as U.S., European Union etc., which is expected to drive the growth of the global laparoscopic power morcellators market over the forecast period. For instance, on February 3, 2021, Olympus America, a medical device company indicated that it supported the U.S. Food and Drug Administration (FDA) published guidance recommendations suggesting that laparoscopic power morcellators in gynecological procedures must be performed using an approved containment device. Olympus Corporation is now the sole manufacturer having a 510(k)-cleared containment laparoscopic power morcellation device in the U.S.

Key Takeaways from Analyst

The laparoscopic power morcellators market is expected to experience steady growth driven by the increasing preference for minimally invasive surgeries among patients and doctors. The rising incidence of uterine fibroids and increasing morcellation procedures for hysterectomies will support the demand for laparoscopic power morcellators.

Safety concerns surrounding the risks of spreading an unsuspected cancer during morcellation procedures may limit market expansion to some extent. Stringent regulations imposed by regulatory bodies globally regarding the use of power morcellators for certain procedures present a challenge.

The Asia Pacific region is projected to witness the fastest adoption of laparoscopic power morcellators due to the improving healthcare infrastructure and rising medical tourism across developing nations. Moreover, growing public awareness about minimally invasive treatments and a large patient pool affected by gynecological conditions create significant opportunities. In North America, stable reimbursement policies and rapid incorporation of advanced surgical technologies by healthcare facilities will drive steady demand. Meanwhile, Europe leads in terms of technological advancements and adoption of innovative morcellation systems.

Market Challenge – Increasing Product Recalls by Regulatory Authorities

Increasing product recalls from regulatory authorities is expected to hamper the growth of the global laparoscopic power morcellators market over the forecast period. For instance, on October 26, 2021, the U.S. Food and Drug Administration (FDA) issued a recall notice for the PneumoLiner device which is intended for use as a tissue containment system during minimally invasive gynecologic laparoscopic surgery, manufactured by Olympus Corporation has received recall notification from the U.S. Food and Drug Administration (FDA) due to manufacturing error.

Market Opportunity – Emerging Markets in Developing Countries

The laparoscopic power morcellators market in emerging markets of developing countries presents a great opportunity for growth. These emerging markets are undergoing rapid urbanization and economic development which is leading to a rise in disposable incomes. As incomes rise, access to healthcare and elective surgical procedures is also increasing. Emerging markets present a unique growth opportunity for laparoscopic power morcellator suppliers. Establishing local manufacturing and distribution networks to cater to these markets early will allow companies to gain a first-mover advantage and build brand loyalty as demand is set to exponentially rise in the coming years due to favorable socioeconomic conditions. This can help power continued leadership in the global morcellators market over the long term.

Discover high revenue pocket segments and roadmap to it: Request sample copy

Application segment is sub-segmented into hysterectomy, myomectomy, and others. The hysterectomy sub-segment is estimated to hold 44.6% of the market share in 2024. Hysterectomy procedures are performed to treat various gynecological conditions such as uterine fibroids, endometriosis, abnormal uterine bleeding, and uterine prolapse. According to recent statistical data, uterine fibroids are very common among women during their reproductive years, affecting over 70% of women by the age of 50. The adoption of minimally invasive techniques such as laparoscopic hysterectomy has significantly increased in the last decade due to advantages like reduced postoperative pain, shorter hospital stay, and quicker recovery time compared to open surgeries. Laparoscopic power morcellators help surgeons to remove the uterus through smaller incisions, improving surgical outcomes. In addition, the growing Geriatric population susceptible to gynecological cancers and disorders also contributes to the demand for hysterectomy procedures worldwide. With rapid advancements in laparoscopic technologies, clinical evidence supporting minimally invasive surgery hysterectomy, and rising patient preference for minimally invasive options, it is expected that hysterectomy will continue to lead the laparoscopic power morcellators market in the foreseeable future.

Insights, By End User: High Volume of Laparoscopic Procedures

End user segment is sub-segmented into hospitals and clinics and surgical centers. The hospitals and clinics sub-segment is estimated to hold 57.4% of the market share in 2024, due to higher volume of gynecological and other laparoscopic surgeries performed across hospitals. A large number of hysterectomy, myomectomy as well as other laparoscopic procedures are carried out in specialty hospitals as well as multi-specialty medical centers. Laparoscopic surgeries require specialized equipment, trained surgeons as well as post-operative care infrastructure available at hospitals. In addition, favorable reimbursement policies for MIS procedures in hospitals, increasing healthcare expenditure in emerging nations, and rise of medical tourism are boosting the adoption of minimally invasive surgeries in hospital settings. Furthermore, ambulatory surgery centers are also emerging as important end users. However, owing to their growing infrastructure and expertise in handling complex laparoscopic cases, hospitals and clinics are likely to continue dominating the laparoscopic power morcellators market in the foreseeable future.

Regional Insights

To learn more about this report, Request sample copy

North America remains the dominant region in the global laparoscopic power morcellators market. The region is estimated to hold 41.5% of the market share in 2024 owing to factors such as the country's well-established healthcare infrastructure and higher expenditure on healthcare. The presence of leading medical device manufacturers such as Ethicon, Medtronic, and Stryker has ensured the vast availability and adoption of laparoscopic power morcellators in the country. Additionally, the large patient population undergoing minimally invasive surgeries and the focus on reducing hospital stay times has driven the demand for such devices in the U.S.

Asia Pacific is the fastest growing regional market for laparoscopic power morcellators. While the overall healthcare infrastructure is still developing in China compared to Western nations, there has been immense focus from both the government and private sector to adopt minimally invasive techniques. This has provided a fertile ground for laparoscopic power morcellators to see increased usage. Local Chinese manufacturers have also strengthened their position in domestic as well as international markets, ensuring high production volumes are met within the country. With rising medical tourism and a growing focus on preventive healthcare, the laparoscopic power morcellators market in China looks set to expand at a rapid pace going forward.

Market Report Scope

Laparoscopic Power Morcellators Industry News

• In November 2022, Olympus Corporation, a medical device company, announced the launch of the more solution Power Morcellator, which is manufactured by TROKAMED GmbH and is available in the U.S. through a distribution agreement with Olympus America, Inc. The more solution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.
• In February 2021, Olympus Corporation, a medical device company, indicated that it supported the U.S. Food and Drug Administration (FDA) published guidance recommendations suggesting that laparoscopic power morcellators in gynecological procedures must be performed using an approved containment device. Olympus is now the sole manufacturer having a 510(k)-cleared containment laparoscopic power morcellation device in the U.S.

*Definition: Laparoscopic power morcellators are Class II medical devices that cut tissue into smaller pieces so that it can be removed through a small incision site during laparoscopic (minimally invasive) procedures. They are primarily used for procedures such as hysterectomy and myomectomy. These morcellators are used in surgeries for removing gallbladder, kidneys, liver, and spleen. These are majorly used in two operational procedures such as hysterectomy (the surgical removal of a woman's uterus), and myomectomy (the surgical removal of uterine fibroids), which are benign tumor growths in the uterus, are two other procedures. The increasing prevalence of uterus fibroid due to various causes such as cancer, polyps, endometriosis, fibroids, and adenomyosis, is projected to drive the growth of the laparoscopic power morcellators market.

Market Segmentation

• Application Insights (Revenue, USD Mn, 2019 - 2031)
  • Hysterectomy
  • Myomectomy
  • Others
•  End User Insights (Revenue, USD Mn, 2019 - 2031)
  • Hospitals and Clinics
  • Surgical Centers 
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Medtronic
  • Karl Storz GmbH
  • Richard Wolf GmbH
  • LiNA Medical
  • Boston Scientific Corporation
  • Nouvag AG
  • Olympus Corporation
  • RUDOLF Medical GmbH
  • Blue endo
  • Hangzhou kangji medical instruments
  • Advin Healthcare